<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01109758</url>
  </required_header>
  <id_info>
    <org_study_id>S282.1.002</org_study_id>
    <secondary_id>2007-006147-52</secondary_id>
    <nct_id>NCT01109758</nct_id>
  </id_info>
  <brief_title>Effects of Fenofibrate on Gene Expression in Healthy Volunteers</brief_title>
  <official_title>Effects of Fenofibrate on Gene Expression Activity and DNA Methylation Profile in Circulating Monocytes of Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Solvay Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Solvay Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess how fenofibrate modify gene expression in circulating
      monocytes of healthy volunteers after 6 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of gene activity of markers in circulating monocytes between Baseline and 6 weeks of fenofibrate treatment</measure>
    <time_frame>Between Baseline and 6 weeks</time_frame>
    <description>The calculation is the difference between the gene expression intensity after 6 weeks of treatment and the gene expression intensity at Baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DNA methylation pattern</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fenofibric acid levels</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urinary protein profile</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fenofibrate</intervention_name>
    <description>145 mg</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female,

          -  To be aged 40-65 years,

          -  To be post menopausal female not receiving hormone replacement therapy,

          -  To have normal homocysteine, folate and vitamin B12 levels at baseline (results
             available for initiation of treatment),

          -  To be in good health as determined by medical history, physical examination, ECG,
             vital signs, serum/urine biochemistry and hematology.

        Exclusion Criteria:

          -  Subjects with clinically relevant evidence of cardiovascular,
             gastrointestinal/hepatic, renal, neurologic/psychiatric or emotional, respiratory,
             urogenital, hematologic/immunologic, HEENT (head, ears, eyes, nose, throat),
             dermatologic/connective tissue, musculoskeletal, metabolic/nutritional, drug
             hypersensitivity, (drug) allergy, endocrine, major surgery or other relevant diseases
             as revealed by medical history, physical examination, and laboratory assessments which
             may interfere with the absorption, distribution, metabolism or elimination of drugs or
             constitute a risk factor when taking the study medication,

          -  Subjects who have been treated with fenofibrate in a previous study,

          -  Subjects who have taken a single dose of an investigational drug within 30 days or
             multiple doses of any investigational drug within 60 days prior to dosing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Director Solvay</last_name>
    <role>Study Director</role>
    <affiliation>Solvay Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site 1</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2010</study_first_submitted>
  <study_first_submitted_qc>April 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2010</study_first_posted>
  <last_update_submitted>April 22, 2010</last_update_submitted>
  <last_update_submitted_qc>April 22, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2010</last_update_posted>
  <responsible_party>
    <name_title>Claire Nee</name_title>
    <organization>Solvay Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Fenofibrate</keyword>
  <keyword>Gene Expression</keyword>
  <keyword>DNA methylation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fenofibrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

